Celldex Therapeutics (CLDX) Cash & Current Investments (2010 - 2026)

Celldex Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $451.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 32.95% year-over-year to $451.5 million in Q1 2026; TTM through Mar 2026 was $451.5 million, a 32.95% decrease from a year earlier, with the FY2025 full-year figure at $518.6 million, down 28.5% from the prior year.
• Cash & Current Investments declined to $451.5 million in Q1 2026 per CLDX's latest filing, from $518.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $823.8 million in Q1 2024 and bottomed at $235.3 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $451.5 million (2026), against an average of $501.2 million.
• Across the five-year window, Cash & Current Investments soared 221.23% in 2024 and plunged 32.95% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $305.0 million in 2022, then surged by 38.91% to $423.6 million in 2023, then surged by 71.22% to $725.3 million in 2024, then retreated by 28.5% to $518.6 million in 2025, then fell by 12.94% to $451.5 million in 2026.
• Per Business Quant, the three latest CLDX Cash & Current Investments figures stand at $451.5 million (Q1 2026), $518.6 million (Q4 2025), and $583.2 million (Q3 2025).